Business Context and Reporting Period
Company: Galectin Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 26, 2019
Reporting Period: Single event date (November 26, 2019)
Business Context: The registrant is a Nevada corporation with its principal executive office in Norcross, GA. Its common stock trades on The Nasdaq Capital Market under the symbol "GALT".
Key Financial Metrics
This filing is a current report regarding a specific event and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The filing reports the issuance of a press release on November 26, 2019, attached as Exhibit 99.1. No material changes to financial position or operations are detailed within the text of this specific Form 8-K.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) but does not include the text of that release. Consequently, no guidance, outlook, management commentary, risks, contingencies, or unusual items are described in the provided source text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) to understand the specific event triggering this filing.
- Verify the company's current cash position and runway in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Confirm the trading status of the "GALT" symbol on The Nasdaq Capital Market.